$PALI
PALISADE BIO, INC.

2023 Q4 Form 10-Q Financial Statement

#000095017023062215 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.558M $1.670M
YoY Change 3.52% -19.52%
% of Gross Profit
Research & Development $1.733M $1.742M
YoY Change -26.03% -9.65%
% of Gross Profit
Depreciation & Amortization $4.000K $0.00
YoY Change 100.0%
% of Gross Profit
Operating Expenses $3.291M $3.778M
YoY Change -14.48% -14.39%
Operating Profit -$3.778M
YoY Change -14.39%
Interest Expense -$4.000K $8.000K
YoY Change -120.0% 100.0%
% of Operating Profit
Other Income/Expense, Net $187.0K $182.0K
YoY Change 73.15% -56.87%
Pretax Income -$2.971M -$3.600M
YoY Change -20.13% -9.8%
Income Tax
% Of Pretax Income
Net Earnings -$2.971M -$3.596M
YoY Change -20.13% -9.9%
Net Earnings / Revenue
Basic Earnings Per Share -$0.49
Diluted Earnings Per Share -$4.81 -$0.49
COMMON SHARES
Basic Shares Outstanding 9.217M 6.856M
Diluted Shares Outstanding 7.344M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.43M $15.31M
YoY Change 0.4% 9.47%
Cash & Equivalents $12.40M $15.30M
Short-Term Investments
Other Short-Term Assets $748.0K $820.0K
YoY Change -17.98% -28.88%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $13.33M $16.27M
YoY Change -9.54% 7.31%
LONG-TERM ASSETS
Property, Plant & Equipment $10.00K $10.00K
YoY Change 0.0% -16.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $490.0K $541.0K
YoY Change -29.39% -27.48%
Total Long-Term Assets $724.0K $801.0K
YoY Change -29.71% -27.71%
TOTAL ASSETS
Total Short-Term Assets $13.33M $16.27M
Total Long-Term Assets $724.0K $801.0K
Total Assets $14.05M $17.07M
YoY Change -10.85% 4.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $698.0K $950.0K
YoY Change -60.32% -44.93%
Accrued Expenses $831.0K $794.0K
YoY Change 44.77% -36.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $158.0K $260.0K
YoY Change 79.55% -26.14%
Total Short-Term Liabilities $2.586M $2.649M
YoY Change -14.14% -24.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $153.0K $340.0K
YoY Change -43.75% 5.26%
Total Long-Term Liabilities $153.0K $340.0K
YoY Change -43.75% 5.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.586M $2.649M
Total Long-Term Liabilities $153.0K $340.0K
Total Liabilities $2.739M $2.985M
YoY Change -16.6% -22.18%
SHAREHOLDERS EQUITY
Retained Earnings $121.5M $118.5M
YoY Change 11.26% 12.64%
Common Stock $93.00K $92.00K
YoY Change 210.0% -88.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.31M $14.08M
YoY Change
Total Liabilities & Shareholders Equity $14.05M $17.07M
YoY Change -10.85% 4.92%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$2.971M -$3.596M
YoY Change -20.13% -9.9%
Depreciation, Depletion And Amortization $4.000K $0.00
YoY Change 100.0%
Cash From Operating Activities -$2.743M -$2.660M
YoY Change -17.03% -12.5%
INVESTING ACTIVITIES
Capital Expenditures $4.000K $0.00
YoY Change -60.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$4.000K $0.00
YoY Change -60.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -134.0K 1.570M
YoY Change -107.82% -86.97%
NET CHANGE
Cash From Operating Activities -2.743M -2.660M
Cash From Investing Activities -4.000K 0.000
Cash From Financing Activities -134.0K 1.570M
Net Change In Cash -2.881M -1.090M
YoY Change 79.84% -112.1%
FREE CASH FLOW
Cash From Operating Activities -$2.743M -$2.660M
Capital Expenditures $4.000K $0.00
Free Cash Flow -$2.747M -$2.660M
YoY Change -17.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
574000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
529000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
486000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
117000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001357459
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33672
dei Entity Registrant Name
EntityRegistrantName
PALISADE BIO, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
52-2007292
dei Entity Address Address Line1
EntityAddressAddressLine1
7750 El Camino Real, Suite 2A
dei Entity Address City Or Town
EntityAddressCityOrTown
Carlsbad
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92009
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
704-4900
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
dei Trading Symbol
TradingSymbol
PALI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9217129
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15312000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12383000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
954000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2350000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
16266000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
14733000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
224000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
300000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
541000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
694000
CY2023Q3 us-gaap Assets
Assets
17067000
CY2022Q4 us-gaap Assets
Assets
15763000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
950000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1759000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
794000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
105000
CY2023Q3 pali Long Term Debt Current Maturities Excluding Related Party Debt
LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt
259000
CY2022Q4 pali Long Term Debt Current Maturities Excluding Related Party Debt
LongTermDebtCurrentMaturitiesExcludingRelatedPartyDebt
88000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2649000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3012000
CY2023Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
2000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
61000
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
212000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
122000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
211000
CY2023Q3 us-gaap Liabilities
Liabilities
2985000
CY2022Q4 us-gaap Liabilities
Liabilities
3284000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9210751
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9210751
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2944306
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2944306
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
92000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
30000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
132523000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
121637000
CY2023Q3 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-118535000
CY2022Q4 pali Retained Earnings Accumulated Income Deficit
RetainedEarningsAccumulatedIncomeDeficit
-109190000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
14082000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12479000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17067000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15763000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
250000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1742000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1928000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5160000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
4204000
CY2023Q3 pali In Process Research And Development
InProcessResearchAndDevelopment
362000
CY2022Q3 pali In Process Research And Development
InProcessResearchAndDevelopment
0
pali In Process Research And Development
InProcessResearchAndDevelopment
362000
pali In Process Research And Development
InProcessResearchAndDevelopment
0
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1674000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2075000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4644000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7259000
CY2023Q3 us-gaap Restructuring Costs
RestructuringCosts
0
CY2022Q3 us-gaap Restructuring Costs
RestructuringCosts
410000
us-gaap Restructuring Costs
RestructuringCosts
0
us-gaap Restructuring Costs
RestructuringCosts
410000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3778000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
4413000
us-gaap Operating Expenses
OperatingExpenses
10166000
us-gaap Operating Expenses
OperatingExpenses
11873000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3778000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4413000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9916000
us-gaap Operating Income Loss
OperatingIncomeLoss
-11873000
CY2023Q3 us-gaap Interest Expense
InterestExpense
8000
CY2022Q3 us-gaap Interest Expense
InterestExpense
4000
us-gaap Interest Expense
InterestExpense
11000
us-gaap Interest Expense
InterestExpense
10000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
190000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
426000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
598000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2453000
CY2023Q3 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
0
CY2022Q3 pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
0
pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
0
pali Financing Cost Derivative Warrant Liabilities
FinancingCostDerivativeWarrantLiabilities
1110000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
182000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
422000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
587000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1333000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3596000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3991000
us-gaap Net Income Loss
NetIncomeLoss
-9329000
us-gaap Net Income Loss
NetIncomeLoss
-10540000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.1
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.1
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-18.4
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-18.4
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7344351
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7344351
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
974197
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
974197
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6031099
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6031099
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
572684
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
572684
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
15800000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3596000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
202000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
14082000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
4211000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3991000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
252000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
12430000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
12479000
us-gaap Net Income Loss
NetIncomeLoss
-9329000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
439000
pali Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
1350000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
14082000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
7365000
us-gaap Net Income Loss
NetIncomeLoss
-10540000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
946000
pali Stock Issued During Period Value Of Common Stock Upon Warrant Exercises
StockIssuedDuringPeriodValueOfCommonStockUponWarrantExercises
1274000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
12430000
us-gaap Net Income Loss
NetIncomeLoss
-9329000
us-gaap Net Income Loss
NetIncomeLoss
-10540000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1000
pali Noncash Lease Expense
NoncashLeaseExpense
76000
pali Noncash Lease Expense
NoncashLeaseExpense
140000
pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
0
pali Issuance Cost Allocated To Warrants
IssuanceCostAllocatedToWarrants
1110000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
212000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
59000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2403000
us-gaap Share Based Compensation
ShareBasedCompensation
439000
us-gaap Share Based Compensation
ShareBasedCompensation
946000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
108000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
213000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-596000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-744000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-184000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
706000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
43000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-418000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-77000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-127000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8387000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10054000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
290000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
524000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
9419000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14401000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2758000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
567000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
333000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11320000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
13544000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2929000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3490000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12409000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10521000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15338000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14011000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15312000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13985000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
26000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
15338000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14011000
us-gaap Interest Paid Net
InterestPaidNet
10000
us-gaap Interest Paid Net
InterestPaidNet
10000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
355000
pali Equity Issuance Costs Included In Accounts Payable
EquityIssuanceCostsIncludedInAccountsPayable
50000
pali Equity Issuance Costs Included In Accounts Payable
EquityIssuanceCostsIncludedInAccountsPayable
683000
pali Non Cash Impact Of Exercise Price Reset On Outstanding Warrants Related To Down Round Provisions
NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions
16000
pali Non Cash Impact Of Exercise Price Reset On Outstanding Warrants Related To Down Round Provisions
NonCashImpactOfExercisePriceResetOnOutstandingWarrantsRelatedToDownRoundProvisions
0
pali Issuance Of Common Stock For Cashless Exercise Of Warrants
IssuanceOfCommonStockForCashlessExerciseOfWarrants
0
pali Issuance Of Common Stock For Cashless Exercise Of Warrants
IssuanceOfCommonStockForCashlessExerciseOfWarrants
1274000
pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
384000
pali Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
55000
pali Fair Value Of Warrants Issued To Underwriter Agent
FairValueOfWarrantsIssuedToUnderwriterAgent
0
pali Fair Value Of Warrants Issued To Underwriter Agent
FairValueOfWarrantsIssuedToUnderwriterAgent
459000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
0
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
58000
pali Net Proceeds From Insurance Financing Arrangements Included In Prepaid And Other Assets And Oher Noncurrent Asstes
NetProceedsFromInsuranceFinancingArrangementsIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAsstes
461000
pali Net Proceeds From Insurance Financing Arrangements Included In Prepaid And Other Assets And Oher Noncurrent Asstes
NetProceedsFromInsuranceFinancingArrangementsIncludedInPrepaidAndOtherAssetsAndOherNoncurrentAsstes
784000
pali Purchase Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
0
pali Purchase Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchaseOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
10000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
118500000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15300000
CY2022Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
184000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">preparation </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">of financial statements in conformity with U.S. GAAP requires the Company to make estimates, judgments, and assumptions that impact the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the balance sheet, and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to clinical trial accruals, contingent consideration liabilities, and its derivative financial instruments. Although these estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">are </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
26000
CY2023Q3 us-gaap Deferred Costs Current
DeferredCostsCurrent
75000
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
114000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions and in money market accounts, and at times balances may exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held nor has the Company experienced any losses in these accounts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
us-gaap Revenue Recognition Software
RevenueRecognitionSoftware
<p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Milestone Revenue</span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company uses the revenue recognition guidance established by ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue From Contracts With Customers</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaborative Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. The Company currently does not have any collaborative arrangements with counterparties that are also considered</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">customers. For arrangements that include amounts to be paid to the Company upon the achievement of certain development milestones of technology licensed by the Company, the Company recognizes such license revenue using the most likely method. At the end of each reporting period, the Company re-evaluates the probability or achievement of any potential milestones and any related constraints, and if necessary, adjusts its estimates of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue in the period of adjustment. For the nine months ended September 30, 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of license revenue related to milestones achieved on licensed technology </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">was recognized as revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. There was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> license revenue recognized by the Company in the </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three months ended September 30, 2023, or the three and nine months ended September 30, 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p>
CY2023Q3 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
285000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3596000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-3991000
us-gaap Net Income Loss
NetIncomeLoss
-9329000
us-gaap Net Income Loss
NetIncomeLoss
-10540000
CY2023Q3 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
-16000
CY2022Q3 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
0
us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
-16000
us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount1
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount1
0
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3612000
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3612000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3991000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3991000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9345000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-9345000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10540000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10540000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7344351
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7344351
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
974197
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
974197
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6031099
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
562000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
581000
CY2023Q3 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
135000
CY2022Q4 pali Prepaid Expenses And Other Current Assets Other Receivables
PrepaidExpensesAndOtherCurrentAssetsOtherReceivables
1438000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6031099
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
572684
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
572684
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.1
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.1
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-18.4
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-18.4
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4967195
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2510249
CY2023Q3 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
160000
CY2022Q4 pali Prepaid Subscriptions And Fees
PrepaidSubscriptionsAndFees
157000
CY2023Q3 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
17000
CY2022Q4 pali Prepaid Software Licenses
PrepaidSoftwareLicenses
54000
CY2023Q3 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
75000
CY2022Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
114000
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
5000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
6000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
954000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2350000
CY2022 pali Cash Receivable For Exercises Of Warrants Included In Prepaid And Other Assets And Other Noncurrent Assets
CashReceivableForExercisesOfWarrantsIncludedInPrepaidAndOtherAssetsAndOtherNoncurrentAssets
1400000
CY2023Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
529000
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
682000
CY2023Q3 pali Other Noncurrent Assets
OtherNoncurrentAssets
12000
CY2022Q4 pali Other Noncurrent Assets
OtherNoncurrentAssets
12000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
541000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
694000
CY2023Q3 pali Accrued Accounts Payable
AccruedAccountsPayable
357000
CY2022Q4 pali Accrued Accounts Payable
AccruedAccountsPayable
69000
CY2023Q3 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
285000
CY2022Q4 pali Accrued Clinical Trial Costs
AccruedClinicalTrialCosts
184000
CY2023Q3 pali Accrued Director Stipends
AccruedDirectorStipends
106000
CY2022Q4 pali Accrued Director Stipends
AccruedDirectorStipends
141000
CY2023Q3 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
0
CY2022Q4 us-gaap Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
180000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
46000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
794000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
574000
CY2023Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
4080908
CY2022Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1055672
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
205201
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.84
CY2023Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.84
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
205201
CY2022Q4 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
1055672
CY2022 pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
26.48
CY2022 pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P3Y3M25D
pali Class Of Warrant Or Right Issued During Period
ClassOfWarrantOrRightIssuedDuringPeriod
5302192
pali Class Of Warrant Or Right Issued During Period Weighted Average Exercise Price
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageExercisePrice
1.75
pali Class Of Warrant Or Right Issued During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightIssuedDuringPeriodWeightedAverageRemainingContractualLife
P4Y7M20D
pali Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
2203993
pali Class Of Warrant Or Right Exercised During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageExercisePrice
0.61
pali Class Of Warrant Or Right Exercised During Period Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightExercisedDuringPeriodWeightedAverageRemainingContractualLife
P0Y8M23D
pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriod
-72963
pali Class Of Warrant Or Right Forfeited Expired Or Cancelled During Period Weighted Average Exercise Price
ClassOfWarrantOrRightForfeitedExpiredOrCancelledDuringPeriodWeightedAverageExercisePrice
2.56
CY2023Q3 pali Class Of Warrant Or Right Number Outstanding
ClassOfWarrantOrRightNumberOutstanding
4080908
pali Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
8.67
pali Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualLife
P4Y4M17D
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
212000
CY2023Q3 pali Changes In Fair Value Of Contingent Consideration
ChangesInFairValueOfContingentConsideration
0
pali Changes In Fair Value Of Contingent Consideration
ChangesInFairValueOfContingentConsideration
0
CY2023Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
212000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
280000000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.64
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
40.32
pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
P5Y7M20D
pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm
P5Y9M21D
pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.0398
pali Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageRiskFreeInterestRate
0.023
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.6875
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.7366
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
43658
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
311.74
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y29D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
510160
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.64
pali Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractualterm2
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualterm2
P9Y8M19D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
10630
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
238.00
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
543188
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.91
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y6M21D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
543188
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
21.91
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y6M21D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
64155
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
165.86
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y6M3D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.93
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
241000000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
192000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
252000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
429000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
946000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M20D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y1M13D
CY2018 pali Collaborations And License Agreements Upfront Fee
CollaborationsAndLicenseAgreementsUpfrontFee
1000000
CY2018 us-gaap Royalty Expense
RoyaltyExpense
6750000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
300000
CY2023Q3 pali Milestone Payments
MilestonePayments
0
CY2022Q3 pali Milestone Payments
MilestonePayments
0
pali Milestone Payments
MilestonePayments
0
pali Milestone Payments
MilestonePayments
0
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
34000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
136000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
93000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
263000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
24000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
239000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
pali-20230930_def.xml Edgar Link unprocessable
pali-20230930_cal.xml Edgar Link unprocessable
0000950170-23-062215-index-headers.html Edgar Link pending
0000950170-23-062215-index.html Edgar Link pending
0000950170-23-062215.txt Edgar Link pending
0000950170-23-062215-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pali-20230930.htm Edgar Link pending
pali-20230930.xsd Edgar Link pending
pali-ex31_1.htm Edgar Link pending
pali-ex31_2.htm Edgar Link pending
pali-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
pali-20230930_lab.xml Edgar Link unprocessable
pali-20230930_pre.xml Edgar Link unprocessable
pali-20230930_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending